Some 25 years ago, Raf was discovered as the transforming principle shared by a murine sarcoma and an avian carcinoma virus. Thus, Raf and tumorigenesis have been connected from the very beginning. Ten years later, the work of many groups instated Raf as the link between Ras, the oncogene most frequently mutated in human cancers, and the mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase (MEK/ERK) module, which with its manifold substrates can contribute to different aspects of carcinogenesis. Finally, the discovery of activating B-Raf mutations in a subset of human cancers, notably melanomas, conclusively established Raf as a major player in tumor development. Recent studies in animal models now show that endogenous C-Raf is essential for the development and maintenance of Rasinduced epidermal tumors. Surprisingly, the role of C-Raf in this case is not that of an mitogen-activated protein kinase activator, but rather that of an endogenous inhibitor of Rho signaling, expanding the range of tumor-related Raf targets. This review focuses on old and new targets of Raf in tumorigenesis.
Introduction
The ERK/MAPK pathway Mitogen-activated protein kinase (MAPK) pathways are signaling platforms through which extracellular signals are routed from the membrane to intracellular targets to engender different biological outcomes. MAPK pathways are three-tiered kinase modules ( Figure 1A ): MAP3K (MAP kinase kinase kinase) is the entry point of the module, and its activation at the membrane starts a cascade in which the signal, in form of phosphorylation, is passed on to the dual specificity kinase MAPK2 (MAP kinase kinase) and from it to the business end of the module, MAPK (MAP kinase). Activated MAPK has many membrane, cytosolic and cytoskeletal substrates whose phosphorylation causes fast short-lived changes in cell shape or metabolism. In addition, activated MAPK can translocate to the nucleus and stimulate transcription, thereby altering the gene expression pattern and causing long-lasting changes in the behavior of the cell. This organization in a three-tiered kinase module allows for a high degree of amplification, with signal strength increasing as one proceeds down the pathway. To date, four distinct MAPK cascades have been described, each named after the individual MAPK component (extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), p38 and ERK5/Big MAPK (BMK)). The ERK pathway was the first signal transduction cascade to be unraveled and delineated from the cell membrane to the nucleus, and its structure is the paradigm for MAP kinase modules in general. Downstream of growth factor receptors, the ERK cascade is initiated by the small G protein Ras, which recruits the MAP3K Raf from the cytosol to the cell membrane, causing its activation by yet unknown kinases. Raf forwards the signal to the MAP2K mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase (MEK) which, in turn, phosphorylates and activates ERK (extracellular signal-regulated kinase). ERK has one of the largest range of effectors ever described for a kinase (at least 180 substrates identified to date), the activation of which, in different combinations, can in principle engender any of the diverse fundamental cellular programs in which ERK has been implicated ( Figure 1B ). Given this bewildering array of possible substrates and outcomes, it is clear that spatiotemporal regulation and signal specificity are key issues in Ras/Raf/MEK/ERK signaling. Signal propagation down the ERK pathway is facilitated by the direct binding of pathway components to one another as well as to a number of scaffolding proteins that have the additional function of targeting the proteins to a specific subcellular compartment (e.g. kinase suppressor of Ras [KSR]) or organelle (e.g. MEK partner-1/p14). Conversely, several inhibitors have been discovered that disrupt Raf/MEK complexes (Raf kinase inhibitory protein [RKIP] ) or prevent the formation of Raf/kinase suppressor of Ras [KSR]/MEK complexes (impedes mitogenic signal propagation [IMP] ; all reviewed in (1)). On balance, the sum of these actions is expected to channel the signal in a more specific direction.
Lower organisms, such as flies or worms, have only one Raf, one MEK and one ERK gene, whereas mammals have three functional raf genes (a-raf, b-raf and c-raf-1), two mek and two erk genes (1 and 2). It is impossible to trace back which of the erk genes is closest to the 'ancestor' gene (2) , but the genes of lower organisms are most similar to b-raf and mek1 (3) . What might be the reason for this redundancy within the pathway? Besides having crucial biological functions of their own, as it is the case for the c-raf-1 gene (see below), these 'younger' components provide additional flexibility to the pathway by engaging in heterodimerization. In response to growth factor stimulation and Ras activation, C-Raf (also known as Raf-1) and B-Raf form heterodimers (4-6) whose MEK kinase activity is higher than that of the respective monomers or homodimers (6) . The existence of stable MEK1:MEK2 heterodimers (3) and the relevance of cytosolic scaffold-induced ERK homodimers for cell proliferation and tumor development have recently been demonstrated (7) .
Signaling through the ERK cascade is terminated by dephosphorylation of the activating residues on Raf, MEK and ERK, which returns the pathway to quiescence. However, signal attenuation is achieved even before dephosphorylation via direct negative feedback mechanism emanating from ERK. In fact, ERK-mediated phosphorylation negatively affects the activity of the Ras guanine nucleotide exchange factor son of sevenless (SOS) (8) as well as the kinase activity of C-Raf (9) and MEK monomers (10, 11) . ERK also provides negative feedback on Raf and MEK heterodimers: by phosphorylating B-Raf on T753, it stimulates the dissociation of C-Raf:B-Raf heterodimers (6); and by phosphorylating MEK1 on T292, a residue not present on MEK2, it downregulates the kinase activity of the MEK2 heterodimer (3) ( Figure 1C ). Whether phosphorylation of one of the subunits regulates the activity of Raf heterodimer is at present unknown. If it did, C-Raf, which is subject to regulation by a number of kinases including ERK (9, 12) , would probably be the target (Figure 2 ).
The Ras/Raf/MEK/ERK pathway and cancer In cancer, the fail-safe mechanisms regulating ERK signaling go awry, resulting in the constitutive activation of the pathway. ERK activation is common in malignancies in which a tyrosine kinase receptor, typically the epidermal growth factor receptor (EGFR), is constitutively active as the result of somatic mutation and/or autocrine signaling and is just about invariably observed in tumors bearing activating somatic Ras or Raf mutations (13, 14) .
Ras is the oncogene most frequently mutated in human cancer, with $33% of all tumors expressing activated Ras (http://www.sanger.ac .uk/genetics/CGP/cosmic). Most cancers with somatic Ras mutations harbor changes in K-Ras (85%, usually cancers of epithelial origin, particularly pancreas, lung and colon), whereas N-Ras mutations are less common (15%, common in melanoma and liver and myeloid cancers) and H-Ras mutations are rare (,1%, usually urogenital tumors) (15) . In normal cells, Ras cycles between an inactive GDP-bound state and an active GTP-bound state. GTP binding is induced by extracellular stimuli via the recruitment of the Grb2-SOS complex to the membrane. Grb2 is an adaptor protein that recognizes phosphotyrosine residues on activated receptor tyrosine kinases, whereas SOS is a guanine nucleotide exchange factor which, when brought in the proximity of Ras, dislodges GDP from the nucleotidebinding site (16) . Displacement of GDP allows Ras binding to GTP, which is favored since the ratio of GTP:GDP in the cell is $9:1.
Because of this, using nucleotide exchange to convert Ras-GTP back to Ras-GDP is not an option. The only possibility is the intrinsic guanosine triphosphatase (GTPase) activity of Ras, which is normally very low, unless stimulated by Ras guanine triphosphatase activating protein (Ras GAP) ( Figure 1B ). Activating Ras mutations in G12, G13 and Q61 all reduces Ras guanosine triphosphatase activity and renders it resistant to GAPs, thereby prolonging the signaling-competent GTP-bound state of Ras (17, 18) .
Besides the Raf/MEK/ERK pathway, Ras-GTP stimulates multiple effectors, the most prominent of which is the phosphoinositide-3 kinase (PI-3K)/AKT pathway. In addition, Ras activates the small guanosine triphosphatases Ral and Rac via the guanine nucleotide exchange factors Ral-GDS and Tiam-1 (19) . The phosphoinositide-3 kinase (PI-3K) pathway (20, 21) and Ral-GDS (22) have been The ERK pathway is stimulated downstream of growth factor receptors (such as the epidermal growth factor receptor), which activate Ras by recruiting the guanine nucleotide exchange factor SOS to the membrane. Activated Ras then recruits and activates Raf, the MAP3K of the ERK cascade. Raf phosphorylates the MAP2K MEK, which transmits the signal to ERK. The ERK pathway comprises three Rafs (A, B and C), two MEKs (1 and 2) and two ERKs (1 and 2). The three Rafs have different abilities to respond to Ras and to phosphorylate MEK, B-Raf ranking first in both cases, followed by C-Raf and A-Raf. Arrow thickness reflects this fact. (C) Heterodimerization and negative feedback in the ERK pathway. Ras activation promotes the formation of B-Raf:C-Raf heterodimers, whose MEK kinase activity is higher than that of homodimers or monomers. ERK-mediated phosphorylation of B-Raf T753 stimulates the dissociation of Raf heterodimers. In addition, ERK-mediated phosphorylation of T292 on MEK1 reduces the activity of MEK1:MEK2 heterodimers. In both cases, negative feedback phosphorylation (in blue, broken arrows) decreases signal strength.
T.S.Niault and M.Baccarini implicated in cell survival, whereas ERK is generally considered the mitogenic branch of Ras signaling. Although targeting Ras itself has proven inefficient, its downstream kinases are deemed more easily 'druggable' and are therefore attractive targets for cancer therapy. However, at least in vitro, Ras-transformed human cells are too 'resourceful' to respond to the inhibition of the MEK pathway only (23) , and although MEK/ERK activation is probably important for tumor development, other Ras effectors may be crucial for maintenance (24) (25) (26) .
Raf and tumorigenesis Structure of Raf and mechanisms of regulation. The products of the three mammalian raf genes are serine/threonine kinases with a common activator, Ras, and a single known common substrate, MEK. Raf proteins have a modular structure comprising three conserved regions (CR) with distinct functions: CR1 and CR2 are both part of the Raf regulatory domain (Figure 2A ). CR1 features the Ras-binding site (Ras-binding domain) necessary for interaction with Ras and membrane recruitment and a cysteine-rich domain (CRD), which is a secondary Ras-binding site and is necessary for the interaction of CR1 with the Raf kinase domain and for Raf autoinhibition (27) . CR2 contains numerous negative regulatory phosphorylation sites (S259 in C-Raf) whose dephosphorylation is prerequisite for Ras binding and Raf activation. Finally, CR3 contains the kinase domain, with the activation segment encompassing threonine and serine residues whose phosphorylation is essential for kinase activation. In addition, phosphorylation of residues in the negatively charged (N) region upstream of the CR3 (S338 and Y341 in C-Raf) is necessary for Raf activation (28) . In the inactive conformation, Raf is hypothesized to form a 'closed' structure, with the regulatory domain, and in particular the cysteine-rich domain (CRD), interacting with the kinase domain ( Figure 2B ). This conformation is stabilized by the binding of the adaptor 14-3-3 to phosphorylation sites in the CR2 (pS259) and in the C-terminal part of the molecule (pS621 in C-Raf) (12, 29) . The latter residue is phosphorylated by C-Raf itself, and this phosphorylation is essential for the stability of the protein (30) . During activation, dephosphorylation of S259 by several phosphatases destabilizes this closed conformation, allowing for Ras binding and membrane recruitment (31) (32) (33) (34) (35) . Yet incompletely defined membrane-associated kinases then phosphorylate the sites in the N region and in the activation segment, stabilizing the 'open' active conformation. All these events, as well as Raf-mediated MEK phosphorylation, take place in membrane nanoclusters induced by active Ras. When these nanoclusters dissolve, active Raf redistributes to the cytosol (36). As mentioned above, Raf activation can be reverted by phosphorylation of negative regulatory residues and/or by dephosphorylation of the activating residues (37) ( Figure 2B ).
The steps described above are necessary for the activation of C-Raf and, in all likelihood, A-Raf. Unlike A-and C-Raf, B-Raf is also regulated at the level of expression via alternative splicing, which gives rise to multiple isoforms differentially expressed in various tissues (38, 39) . Splicing also regulates B-Raf activity: isoforms containing exon 8b are strongly phosphorylated on the S365 14-3-3-binding site, leading to increased interaction between the regulatory domain and the kinase domain of B-Raf and to a reduction in kinase activity (40) . At the posttranslational level, less phosphorylation events are required: the N region of B-Raf is negatively charged prior to activation due to the constitutive phosphorylation of the relevant serine residue and to the presence of an aspartate at the position of C-Raf's Y341; therefore, dephosphorylation of negative regulatory sites (40) and Ras binding are probably to be the only requirements for B-Raf activation (28) .
Among the three Raf kinases, B-Raf binds best to Ras (41, 42) and is the most active in phosphorylating MEK in vitro (28, 39, 43) and in transforming NIH 3T3 cells in culture (39, 44) . As a consequence of all these, B-Raf (alone or in the context of B-Raf-containing Raf heterodimers) is probably to be the most effective MEK kinase in vivo (45) (46) (47) , and this prominent role may account for the fact that somatic mutations associated with cancer are relatively frequent in B-Raf but extremely rare in the other two family members (43) .
B-Raf-an oncogene addicted to MEK. Over the years, B-Raf has been increasingly associated with cancer development. The gene has been found mutated, duplicated or aberrantly spliced in specific subsets of cancers (48-50). Large-scale studies found BRAF gene Overview of C-Raf activation. C-Raf is kept quiescent by intramolecular autoinhibition, stabilized by the binding of 14-3-3 proteins to the pS259 and pS621 residue. Upon mitogenic stimulation, Ras and phosphatases work together to release autoinhibition and recruit C-Raf to the membrane, where yet incompletely defined upstream kinases phosphorylate the activating residues. 14-3-3 stabilizes pS621 and promotes ATP binding to C-Raf. Following MEK/ERK activation, C-Raf is phosphorylated on negative regulatory sites, which desensitize the kinase. The prolyl isomerase Pin1 renders C-Raf accessible for PP2A, which dephosphorylates the ERK-dependent negative sites. C-Raf ultimately reverts to its 'closed' conformation upon rephosphorylation of S259 (mediated for instance by AKT or protein kinase A [PKA]) binding to 14-3-3. Negative regulatory residues are depicted in blue, and residues implicated in kinase activity or activation are in magenta.
Targets of Raf in tumorigenesis mutated at high frequency in malignant melanoma (43%), papillary thyroid carcinomas (48%), serous micropapillary ovarian carcinoma (38%) and colorectal serrated polyps (60%) and at lower frequency in liver, pancreas, stomach, non-small-cell lung cancer, glioma and leukemia (http://www.sanger.ac.uk/genetics/CGP/cosmic). Most BRAF mutations localize to the kinase domain and increase the kinase activity of B-Raf toward MEK. A valine-to-glutamate substitution in the glycine-rich loop is the most frequent BRAF mutation (V600E, 90% of the cases (48)). The crystal structure of B-Raf has revealed an intramolecular interaction between the glycine-rich loop and the activation segment that maintains B-Raf inactive. Phosphorylations within the activation segment or amino acid substitutions such as V600E break this intramolecular interaction, activating B-Raf (51). Moreover, B-Raf V600E does not associate with the inhibitor Sprouty2 and is therefore insensitive to negative feedback mechanisms (52, 53) . Other, less common BRAF mutations have reduced kinase activity, yet they can drive MEK/ERK activation when transfected into cells by stimulating the kinase activity of C-Raf in the context of Raf heterodimers (5, 48) . The importance of (hetero)dimer formation for Raf activation has been recently underscored by a study showing that the active form of the Raf catalytic domain is a side-to-side dimer and that mutations that favor dimer formation increase the catalytic activity of B-Raf WT in trans (54) . B-Raf V600E also associates with endogenous C-Raf; in this case, however, the outcome is very different: C-Raf inhibits B-Raf V600E kinase activity, ERK activation and the proliferation of human melanoma cells expressing B-Raf V600E (55) . Thus, heterodimerization of tumor-associated B-Raf mutants with endogenous C-Raf is a double-edged sword, and the outcome depends on the nature of the B-Raf mutation.
Expression of B-Raf V600E in cultured melanocytes induces the activation of the downstream MEK/ERK pathway (56) . High levels of activation of this pathway, however, have been shown to promote senescence or apoptosis rather than proliferation (57-61) both via cell-autonomous mechanisms, such as the activation of the p16 INK4a /p19 ARF locus encoding for tumor suppressors (62) , and via autocrine/paracrine pathways, such as the secretion of insulin-like growth factor binding protein 7 (IGFBP7) (63) . Consistent with this, B-Raf V600E is frequently found in benign melanocytic hyperplasia (nevi) (64) , lesions whose cells are in a growth-arrested senescentlike state ( Figure 3A) . B-Raf V600E -induced senescence can be overcome by cooperative events, the most common of which are the loss of tumor suppressors, notably p16 INK4a , p53 (65-68) and phosphatase and TENsin homolog (PTEN) (69, 70) , and the overexpression of proto-oncogenes such as c-myc (71) or, in colorectal carcinoma cell lines, Rac1b (72) . In addition, Akt3, often activated in many melanomas, can cooperate with B-Raf V600E by phosphorylating it and decreasing its activity to a level that promotes proliferation rather than senescence (73) . Finally, dimerization with C-Raf (55) could be an additional mechanism to modulate B-Raf V600E -induced ERK activation and keep it at a tolerable level until senescence/apoptosis is disabled. In support of this idea, the C-Raf:B-Raf ratio is reduced in human melanoma cells (55) .
Recently, a new target of the B-Raf V600E /ERK pathway with a potentially strong impact on tumorigenesis has been identified by the Cantley group (74) . In melanoma cells, ERK-mediated phosphorylation of LKB1 suppresses activation of AMP-activated protein kinase (AMPK). This allows mammalian Target of Rapamycin (mTOR) signaling and protein synthesis to continue under conditions of metabolic stress such as those encountered by developing tumors. Intriguingly, ERK phosphorylates LKB1 only in the context of a complex containing B-Raf V600E (74) , resulting in a competitive growth advantage for cells expressing this particular mutation.
Besides driving proliferation, B-Raf V600E plays an important role in tumor invasion and in tumor-stroma interactions, such as promoting angiogenesis and creating an immune-privileged microenvironment. Several proteins regulating cell migration such as Rdn3, PlexinB1 or Minerva/FAM129B are upregulated in cell expressing B-Raf V600E ; conversely, depletion or chemical inhibition of B-Raf V600E impairs integrin signaling, preventing melanoma cell anchorage and metastases (75) (76) (77) (78) . Moreover, B-Raf V600E modifies the tumor environment by inducing the expression of the angiogenic factors hypoxia-inducible factor 1a (HIF-1a) (79) and vascular endothelial growth factor (VEGF) (80, 81) as well as the upregulation of the cytokines interleukin-8 and interleukin-10 in several cancer cell lines (82) ( Figure 3A ). All these effects can be reversed both by silencing the BRAF gene and by chemical inhibition of MEK and are therefore mediated via the MEK/ERK module (78, (80) (81) (82) .
The oncogenic role of activated B-Raf has been confirmed in vivo. In an unbiased genetic screen for genes involved in solid tumor development in the mouse, b-raf scored as the gene most frequently disrupted by the Sleeping Beauty transposon, used to drive somatic insertion mutagenesis. Transposon insertion resulted in a constitutively active B-Raf lacking the N-terminal regulatory region (83) . In addition, the oncogenic role of the B-Raf V600E mutation has been demonstrated by two conditional knockin mouse strains in which Cre-mediated recombination allows the expression of the mutant transcript from the endogenous BRAF locus. So far, myeloid leukemia leading to the rapid death of the animals has been shown to follow expression of B-Raf V600E driven by an interferon-responsive Cre (Mx-Cre) (84) , whereas the activation of B-Raf V600E in pulmonary epithelium induces benign lung adenomas that show sign of senescence. In the latter model, ablation of p53 or p16 INK4a /p19 ARF promotes tumor progression to adenocarcinoma, highlighting the importance of overcoming senescence in B-Raf-induced tumorigenesis (68) .
This result has been confirmed by the analysis of the same knockin mouse models targeting the mutation to the melanocytic compartment in which B-Raf mutations are most frequent in humans. Endogenous levels of B-Raf V600E in mouse melanocytes drive benign nevi formation (69) . However, in one model, the benign nevi fail to progress to melanoma unless PTEN is silenced, in which case, the tumors become invasive and metastasize to lymph node and lung (69) , whereas in the other, 70% of the mice spontaneously develop melanoma with features of invasiveness. The cooperating events allowing melanoma formation in this model are currently unknown but appear to be independent of the tumor's p16 INK4a status (85) . Benign nevi also spontaneously progress to melanoma in a mouse model that expresses a human BRAF V600E transgene in the melanocyte compartment. In this model, the cooperating events observed are increased ERK and AKT activation, the latter suggesting an involvement of PTEN, and genomic deletion of the p16 INK4a /p19 ARF locus, pointing again to senescence as the major hurdle in BRAF V600E -induced melanomagenesis (86) .
Besides promoting melanoma development, B-Raf V600E is also essential for tumor maintenance. Knockdown or chemical inhibition of B-Raf V600E leads to stasis or regression of patient-derived and tumor cell line xenografts expressing B-Raf V600E (87) (88) (89) (90) . B-Raf inhibitors and silencing were much less effective against xenograft-harboring mutations in other genes, e.g. Ras, underscoring the concept that knowledge of the molecular determinants driving a specific tumor is important for determining the therapeutic options of the patient (91) .
Although the role of B-Raf V600E in cancer has been extensively studied, not much is known about the involvement of endogenous wild-type B-Raf in tumorigenesis driven by mutations in other genes. Endogenous B-Raf drives ERK activation and cell proliferation in uveal melanoma cell lines in the absence of RAS or RAF mutations (92); on the other hand, B-Raf is dispensable for MEK/ERK activation and proliferation in melanoma cell lines harboring activating KRAS or NRAS mutations (93) and is required for ERK activation, but not for proliferation, in non-small-cell lung cancer cell lines harboring KRAS mutations (94) . In the latter cases, C-Raf is the relevant Ras effector. In addition, we have recently shown that endogenous B-Raf is essential for tumor proliferation and tumor progression in a mouse model of pancreatic islet carcinoma driven by the loss of function of the tumor suppressors p53 and Rb. Conditional ablation of B-Raf in the b-cells of the Langerhans islets results in reduced MEK/ERK activation. Surprisingly, this does not affect cell proliferation per se, but it instead impairs the production of proangiogenic factors such as vascular endothelial growth factor (VEGF) and transforming growth T.S.Niault and M.Baccarini factor (TGF)-b as well as that of extracellular matrix components ( Figure 3B ). The resulting reduced blood vessel density and stromal responses restrain tumor proliferation and delay tumor progression (47) . The role of B-Raf in tumor-associated angiogenesis is reminiscent of its essential role in embryogenesis, where B-Raf is required for hypoxia-inducible factor 1a stabilization, vascular endothelial growth factor (VEGF)-A expression and the development of the labyrinthine layer of the placenta (45) and suggests that B-Raf inhibitors may be used in the co-therapy of tumors whose growth depends on an angiogenic switch.
C-Raf-an example of non-oncogene addiction. C-raf was initially discovered as the cellular genes captured by two transforming retroviruses, the naturally occurring avian retrovirus Mill Hill 2 (MH2) (95) and a murine sarcoma virus (MSV) isolate 3611, recovered from a mouse presenting with lung adenocarcinomas and histiocytic lymphoma in an oncogene capture experiment (96) . Both viruses had hijacked the catalytic domain of C-Raf and expressed it as Gag-Raf fusion proteins lacking the N-terminal regulatory domain. These proteins had constitutive serine/threonine kinase activity, making v-raf the first serine/threonine kinase oncogene to be discovered (97) . The transforming potential of truncated c-raf has since been confirmed in vivo by showing that it can cooperate with myc to induce hematopoietic tumors in newborn mice (98) and by a plethora of experiments in cultured cells (44, (99) (100) (101) (102) to cite but a few seminal contributions. Oncogenic C-Raf promotes proliferation, survival, epithelial/mesenchymal transition and invasion (44, (100) (101) (102) (103) (104) (105) (106) (107) , at least partially through an autocrine/paracrine response (108) (109) (110) , which, besides exerting positive feedback on the Ras/Raf/MEK/ERK cascade, allows cross talk with other pathways, such as the stress kinases and the nuclear factor-kappaB (NF-jB) pathway (111, 112) . Practically, all the effects of the oncogenic C-Raf kinase can be ascribed to the activation of the MEK/ERK pathway. Since high levels of MEK/ ERK activation result in senescence, oncogenic C-Raf induces senescence in cultured cells unless tumor suppressor/cell cycle control pathways are inactivated (57) (58) (59) (60) (61) .
In vivo, both the overexpression of wild-type C-Raf and the expression of the truncated oncogenic form in alveolar pneumocytes, driven 
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by the human surfactant protein-C promoter, induce the development of lung adenomas (113) , which can be delayed by Bcl-2 deletion (114) . Intriguingly, disruption of cell adhesion by interfering with E-cadherin expression (by tissue-restricted knockout) or function (by expressing dominant negative E-cadherin) drives massive tumor angiogenesis and metastasis in this model, showing that cell-cell adhesion is a major hurdle to tumor progression in this system (115) . More recently, a recombinant retrovirus containing the constitutively active kinase domain of C-Raf has been reported to induce glioma formation in mice when targeted to neural precursors (116) . Reminiscent of the effects of the expression of activated B-Raf in vivo, the constitutively active C-Raf kinase domain induces high levels of MEK/ERK activation (113, 116) , which, at least in the case of the lung tumors, are crucial for tumor development (117) . In addition, also similar to the B-Raf models, tumor development is accelerated by the loss of tumor suppressor genes, notably p53 (118) and p19 ARF (116) , or by AKT activation (116) . Together, these results suggest that both activated B-Raf and C-Raf mediate tumorigenesis by inducing MEK/ERK activation in vivo and that cooperating events involving the escape from senescence and/or the suppression of apoptosis are needed to counterbalance the negative effects of high-level MEK/ ERK signaling.
Of note, whereas it is well established that B-Raf signals primarily via MEK/ERK, C-Raf has several other effectors with tumorigenic potential, mostly molecules promoting survival ( Figure 4A ). Oncogenic C-Raf has reportedly interacts with inhibitor of j-B and MEK Kinase 1, resulting in the activation of the nuclear factor-kappaB signaling pathway (119, 120) . Moreover, a mitochondrial pool of C-Raf has been shown to protect cells from apoptosis (121, 122) . C-Raf can be targeted to the mitochondria via its interaction with Bcl-2 (123) and/or the Bcl-2-interacting protein BCL2-associated athanogene (BAG-1) (124, 125) . In addition, selected growth factors can promote C-Raf mitochondrial localization via p21-activated kinase (PAK)-induced phosphorylation (126, 127) . One candidate substrate of mitochondrial C-Raf is the proapoptotic Bcl-2 family member Bcl-2 antagonist of cell death (BAD), whose phosphorylation precludes its localization to the mitochondria (123,128) ; however, several other kinases are capable of phosphorylating BAD, the most prominent being AKT/protein kinase B (PKB) (129) . In addition, C-Raf has been shown to interact with apoptosis signal-regulating kinase 1 (ASK-1) (130), a kinase implicated in the proapoptotic response to genotoxic stress and reactive oxygen species (131) . This interaction takes place at the mitochondria (132) and results in ASK-1 inhibition in cultured cells (130, 132) . In vivo, ASK-1 is reportedly hyperactive in C-Rafdeficient cardiomyocytes, and this correlates with increased apoptosis (133) . ASK-1 inhibition is independent from C-Raf's MEK kinase activity (130) , but it is yet unclear whether it involves phosphorylation of ASK-1 by C-Raf. Thus, although the question of the relevant substrates is yet incompletely understood, C-Raf signaling could contribute to tumor development via the inhibition of apoptosis. However, since the activation status of NF-jB, BAD and ASK-1 in the C-Raf-induced tumors has not been investigated, it is currently unclear whether they may contribute to tumor development in vivo.
C-Raf has also been shown to interact with, and inactivate, the retinoblastoma tumor suppressor protein (Rb (134)). C-Raf-induced Rb phosphorylation is independent from the activation of the MEK/ ERK module as well as of cyclin-dependent kinases. In growth factorstimulated cells, C-Raf binds to E2F1-regulated promoters and results in the dissociation of the chromatin-remodeling protein Brg-1, potentially leading to their derepression (135) . Importantly, the C-Raf-Rb interaction is increased in non-small-cell lung cancer tumors (136); and both a C-Raf peptide (C-Raf aa 10-18 (136)) and small molecular compounds that disrupt interaction prevent the proliferation in vitro and the growth in nude mice of a large panel of human tumor cell lines, with the notable exception of those lacking a functional Rb protein (137) . Thus, the interaction between C-Raf and Rb is a promising target for future molecule-based therapies.
All these observations in cultured cells and mice support a causal role for activated C-Raf in tumorigenesis. However, unlike BRAF, CRAF mutations are rare in human cancer, appearing with an overall frequency of 1% (http://www.sanger.ac.uk/genetics/CGP/cosmic). Four mutations have been detected in human cancer cell lines (P207S, V226I, Q335H and E478K (43)); more recently, two germline mutations (S427G and I448V) have been detected in patients with therapyrelated acute myeloid leukemia (138) . E478K and S427G C-RAF show increased MEK kinase activity, but all mutant proteins performed poorly, or not at all, in oncogenic transformation assays. Interestingly, somatic loss of Raf kinase inhibitory protein (RKIP) (139), a negative regulator of C-Raf-mediated MEK/ERK activation, has been recently identified as the cooperating event allowing tumor formation in the The essential role of endogenous C-Raf is to bind to, and inhibit, three other serine/threonine kinases operating in other pathways. These are mammalian STE20-like kinase 2 and ASK-1, whose inhibition by C-Raf restrains apoptosis, and the cytoskeleton-based Rho effector Rok-a. C-Raf-mediated inhibition of Rok-a is necessary to maintain cell shape and motility, to protect cells from Fas-induced apoptosis and to restrain keratinocyte differentiation and allow the development and maintenance of Ras-induced epidermal tumors.
T.S.Niault and M.Baccarini acute myeloid leukemia patients carrying the germline CRAF mutations S427G and I448V (140) . In addition, an activating fusion of the kinase domain of CRAF with SRGAP3 has been reported recently in pilocytic astrocytoma (141) . Thus, mutational activation of CRAF is an extremely rare event in human cancer.
Overexpression of CRAF has been observed in squamous cell carcinoma (142) and lung adenocarcinomas (143) and, together with A and BRAF, in astrocytic tumors (144) . Most interestingly, recent reports show that an increase in CRAF expression correlates with metastatic progression (145) and with acquired resistance to BRAF inhibitors in melanoma (146) . Thus, a role for CRAF overexpression in human cancer may be emerging, although clearly more data are needed to confirm this possibility.
So does C-Raf play a role in tumorigenesis, although it cannot be considered a prime oncogene?
It is possible that wild-type C-Raf has essential functions downstream of prime oncogenes. In support of this, cultured melanoma cells containing Ras mutations depend on C-Raf for MEK activation (93) . In addition, melanoma lines containing BRAF mutations with weak kinase activity, which are capable of activating C-Raf (5), undergo apoptosis accompanied by reduced BAD phosphorylation/Bcl-2 expression upon CRAF silencing (147) . Although the number of cell lines investigated is limited, the latter data suggest that MEK/ERKindependent functions of C-Raf may play at least a supportive role in tumorigenesis.
The availability of conventional and conditional c-raf knockout mice has been instrumental in discovering several of these MEK/ ERK-independent functions. Besides the regulation of ASK-1 mentioned above (130, 133) , C-Raf is essential in attenuating the activity of two other enzymes: the proapoptotic kinase mammalian STE20-like kinase 2 (MST2) (148, 149) , a regulator the Lats/Yes kinaseassociated protein (YAP) pathway (150) , and the cytoskeleton-based kinase Rok-a, a Rho effector involved in migration (151) as well as in the trafficking of the death receptor Fas and in the modulation of Fasinduced apoptosis (152) (Figure 4B ). In the absence of C-Raf, both kinases are hyperactive, resulting in two main cellular phenotypes observed, namely reduced migration (151) and increased apoptosis (148, 149, 152) . In particular, interfering with Rok-a, by chemical inhibition, by gene silencing or by the expression of a dominant negative mutant corrects all the defects of C-Raf-deficient cells (151, 152) . Intriguingly, the attenuation of MST2 and Rok-a activity by C-Raf is independent of its kinase activity. Although this does not exclude that the C-Raf kinase may play additional roles in the MEK/ERK or in other pathways, it implies that its kinase-independent functions are the essential ones, at least in non-transformed cells. In support of this, a knockin mouse expressing a C-Raf protein that cannot be activated by growth factors is viable and does not show any phenotype (153) .
At this point, one obvious question was whether C-Raf is essential for tumorigenesis in vivo and, in the affirmative case, whether its role would depend on its kinase activity or not. This has been addressed in vivo in the epidermis in two autochthonous Ras-induced skin tumor models. C-Raf turns out to be the first downstream target to which Ras is absolutely addicted. Not only is C-Raf-deficient epidermis not permissive to Ras-driven carcinogenesis but also C-Raf ablation induces the complete regression of established tumors, which never relapse regardless of the persisting Ras activation (154) .
Both the physiological role of C-Raf in Ras-induced tumorigenesis and the underlying mechanism were entirely unexpected: C-Raf is surprisingly dispensable for tumor cell survival and for proliferation as well as for the activation of the ERK pathway. Instead, C-Raf is absolutely required to block differentiation, thus allowing the expansion of progenitor populations. Mechanistically, C-Raf works by counteracting the activity of its interactor kinase Rok-a, which when hyperactive prevents the activation of STAT3 and Myc, forcing keratinocytes to exit the cell cycle and differentiate ( Figure 5 ). Importantly, Rok inhibition allows Ras-induced dedifferentiation in C-Raf-deficient epidermis, demonstrating that Rok is the key player in C-Raf-mediated inhibition of keratinocyte differentiation. Thus, Ras-driven skin tumorigenesis requires C-Raf as an endogenous Rok inhibitor necessary to prevent differentiation (154) .
Luckily, C-Raf is dispensable for epidermal homeostasis (151) . Thus, molecule-targeted therapies including C-Raf interference or allosteric inhibitors disrupting the C-Raf:Rok-a complex could in principle be designed which, together with conventional therapies, might be useful at least in the treatment of Ras-driven skin epidermis tumors.
At the molecular level, the mechanism by which C-Raf inhibits Rok-a is entirely novel. Much like C-Raf, Rok-a is a modular kinase kept inactive by the intramolecular interaction between the kinase domain and a negative regulatory domain. Upon activation, intramolecular inhibition is relieved and the kinase domain is free to accept and phosphorylate substrates. When C-Raf and Rok-a are activated concomitantly, as it is the case in growth factor-treated cells or in cells and tissue containing active Ras, the N-terminal regulatory domain of C-Raf, which bears similarity to Rok-a's own autoinhibitory domain, binds to the kinase domain of Rok-a, providing inhibition in trans and attenuating Rok-a downstream signaling ( Figure 5 ). The kinase domain of C-Raf is dispensable for Rok-a binding and inhibition, making the C-Raf:Rok-a complex an unprecedented example of 
kinase regulation mediated by physical interaction rather than by the phosphorylation of negative regulatory residues (155) .
Conclusions
The results of the past few years have revealed that B-Raf and C-Raf play distinct roles in tumorigenesis. Both Raf kinases, if appropriately activated in an experimental setting, are able to drive transformation of cultured cells and tumorigenesis in vivo via the activation of the MEK/ERK module. In line with this, somatic mutations activating B-Raf and resulting in increased MEK/ERK signaling are observed with high frequency in a subset of human tumors. On the other hand, C-Raf mutations are extremely rare, and their role in tumorigenesis unclear. So far, the downstream effects of both oncogenic and endogenous B-Raf in tumorigenesis depend on only one effector, namely MEK; in other words, B-Raf is 'addicted' to MEK. In contrast, endogenous C-Raf is essential for tumor development due to its effects on a broader range of downstream targets and functions. These include alternative substrates, such as Rb, which modulates cell cycle entry and angiogenesis, and interacting kinases inhibited by C-Raf in a kinase-independent manner, such as Rok-a, which regulates cell differentiation in epidermal tumors. This is consistent with the hypothesis that B-Raf is the archetypal MEK kinase, linking Ras directly to the MEK/ERK module, whereas C-Raf has evolved into a less efficient MEK kinase, dedicated to the cross talk and modulation of parallel pathways. The investigation of Raf transgenic mouse models continues to identify novel effectors and interactors of the Raf proteins and their functions in tumorigenesis, providing us with attractive opportunities for the development of molecule-based alternative anticancer therapies, leading not only to reduced proliferation but also to increased differentiation or apoptosis. 
